Table Published: February 10, 2016
The table below displays the annual support level for various research, condition, and disease categories based on grants, contracts, and other funding mechanisms used across the National Institutes of Health (NIH).
At the request of Congress, the NIH embarked on a process to provide better consistency and transparency in the reporting of its funded research. This new process, implemented in 2008 through the Research, Condition, and Disease Categorization (RCDC) system, uses sophisticated text data mining (categorizing and clustering using words and multiword phrases) in conjunction with NIH-wide definitions used to match projects to categories. RCDC use of data mining improves consistency and eliminates the wide variability in defining the research categories reported. The definitions are a list of terms and concepts selected by NIH scientific experts to define a research category. The research category levels represent the NIH’s best estimates based on the category definitions. For a federal source of case-by-case burden data on a broad variety of diseases, conditions, and populations, please see the Centers for Disease Control and Prevention (CDC) FastStats site.
The NIH does not expressly budget by category. The annual estimates reflect amounts that change as a result of science, actual research projects funded, and the NIH budget. The research categories are not mutually exclusive. Individual research projects can be included in multiple categories so amounts depicted within each column of this table do not add up to 100 percent of NIH-funded research.
The table shows historical data for FY 2012 through FY 2015. The FY 2016-2017 estimates are based on RCDC actual data.
Total Number of Research/Disease Areas: 265
Click here for instructions on how to use the data table below.
|[*]||The minimum reporting threshold for a specific disease/condition is $500,000. Reporting of $0 does not indicate that no research is being conducted.|
|[+]||Indicates a new category. Funding support data not available prior to the initial year reported.|
|1/||Name revised in FY 2015 to account for more inclusive definition of research addressing the harms and benefits related to alcohol use.|
|2/||New categories established pursuant to Section 230, Division G of the Consolidated and Further Continuing Appropriations Act of 2015 as related to reporting of NIH initiatives supporting the National Alzheimer’s Project Act (NAPA) https://aspe.hhs.gov/national-alzheimers-project-act. The new Alzheimer’s Disease Related Dementias (ADRD) category reflects the sum of the three existing RCDC categories: Frontotemporal Dementia (FTD), Lewy Body Dementia and Vascular Cognitive Impairment/Dementia – where duplicates are removed. The new category Alzheimer’s Disease including Alzheimer’s Disease Related Dementias reflects the sum of the two existing RCDC categories: Alzheimer’s Disease and the above new Alzheimer’s Disease Related Dementias (ADRD) – where duplicates are removed.|
|3/||Reporting for this category does not follow the standard RCDC process. The total amount reported is consistent with reporting requirements for this category to the U.S. Office of Management & Budget (OMB). The project listing does not include non-project or other support costs associated with the annual total for this category. Additional information on this category is available at https://www.niaid.nih.gov/topics/biodefenserelated/pages/default.aspx.|
|4/||Includes research funded from the Type 1 diabetes appropriation. These are project listings only.|
|5/||Reporting for this category does not follow the standard RCDC process. Spending for this category is reported consistent with U.S. Office of National Drug Control Policy (ONDCP) requirements. This category includes only projects funded by NIDA. More information on this area is available at https://www.drugabuse.gov/drugs-abuse. FY 2014 actual and FY 2015 estimate reported in RePORT can differ from levels identified in the FY 2016 Drug Control budget submission for those fiscal years where comparable adjustments have been applied.|
|6/||Reported total for this category encompasses research for anorexia, bulimia nervosa, binge eating disorders, and eating disorders not otherwise specified.|
|7/||Name revised in FY 2015 and definition refined. Category merges projects identified as Foodborne Illness with relevant projects from the prior “Food Safety” category. Historical data is maintained in separately to assure that information for predecessor categories is not conflated with the merged category.|
|8/||Reporting for this category does not follow the standard RCDC process. This category assigns project funding according to populations tracked by gender or ethnicity. The databases used to track gender/ethnicity are complex are not currently compatible with the RCDC system.|
|9/||The total for AIDS research includes both extramural and intramural research (including research management and support, Management Fund, and Service & Supply Fund), buildings and facilities, research training, and program evaluation, as well as research on the many HIV-associated co-infections and co-morbidities, including TB, hepatitis C, and HIV-associated cancers. It also includes all of the basic science underlying this research. Other RCDC categories are not reported this way; thus the total for AIDS-related research is not comparable to spending reported for other RCDC diseases. More information on this area is available at https://www.oar.nih.gov/hivaids/.|
|10/||This category includes projects that are focused on basic, pre-clinical, clinical, biomedical, health services, behavioral, and social research relevant to sexual and gender minority (SGM) populations. The SGM population – often referred to as LGBT, is asterisked to recognize the diversity in membership as well as sensitivities associated with the variety of descriptive names in use by the medical communities and general public. LGBT research pertains to people whose sexual orientation is not exclusively heterosexual, i.e. lesbian, gay, and bisexual persons. Research projects can likewise focus on individuals whose gender identity differs from the sex originally assigned to them at birth, gender non-conforming or gender variant, or who may not self-identify as LGBT (such as queer, questioning, two-spirit, asexual, etc.). Research also can cover individuals who are born with conditions in which development of chromosomal, gonadal, or anatomic sex is atypical, i.e. people who identify themselves as intersex or with differences/disorders of sex development (DSD). DSD can include, but are not limited to: Y chromosome aneuploidy, congenital adrenal hyperplasia, complete androgen insensitivity, partial androgen insensitivity, gonadal dysgenesis, mixed gonadal dysgenesis, hypospadias, Klinefelter syndrome, Turner syndrome, 5aRD2 deficiency, aromatase defects, MRKH syndrome and gynecomastia.|
|11/||Reporting for this category does not follow the standard RCDC process. This category uses a non-standard approach involving subject matter expert reviews of manually collected project listings.|
|12/||The data provided reflects funding amounts reported by the NIH RCDC process for this category. Actual and estimate levels presented on this site supersede estimates detailed in OMB MAX DE application tables that may have been based on preliminary funding support information.|
|13/||Reporting for this category does not follow the standard RCDC process. This category includes all spending reported under the Drug Abuse category as well as projects categorized under the broader area of Substance Abuse. These are project listings only. More information on this area is available at https://www.drugabuse.gov/drugs-abuse.|
|14/||Prior to FY 2011, this category's title was "Health Effects of Climate Change". The title was revised to more accurately reflect the content of the research conducted and facilitate reporting spending data in response to requests tracking climate change adaptation.|
|15/||Name revised in FY 2013 to reflect current scientific terminology.|
|16/||Reporting for this category does not follow the standard RCDC process. Spending for this category is reported consistent with U.S. Office of National Drug Control Policy (ONDCP) requirements. This category includes only projects funded and administered by NIAAA. This category represents a subset of spending reported under the RCDC Underage Drinking category and involves manual review of the project listing by subject matter experts. More information on this area is available at https://www.niaaa.nih.gov/research/major-initiatives/underage-drinking-research-initiative. The FY 2015 actual or and FY 2016 estimate display in RePORT can differ from levels identified in the FY 2017 Drug Control budget submission for those fiscal years where either comparable adjustments have been applied or historical data was refined.|
|17/||Name revised in FY 2015 from “Clinical Trials”.|
|18/||Name revised in FY 2015 from “Neuropathy”.|
|19/||Estimates of United States disease burden are provided as mortality and prevalence figures for calendar year 2014. Figures for mortality data are drawn from the National Vital Statistics System (NVSS), and indicate the number of deaths in which a particular disease or condition was mentioned on a deceased individual’s death certificate. Prevalence figures are drawn from National Health Interview Survey(NHIS) responses and report the percentage of respondents who indicated that they were affected by a particular health condition. Estimates of mortality and prevalence are not available for all NIH spending categories. Further descriptions of these disease statistics can be found here.|
|[**]||indicates that prevalence was measured in children < 18|